Related Experiment Videos
Discoveries, drugs and skeletal disorders
1Department of Medicine, McGill University and McGill University Health Centre, 687 Pine Avenue, West Montreal, Quebec, Canada H3A 1A1. david.goltzman@mcgill.ca
Nature Reviews. Drug Discovery
|October 3, 2002
Summary
Bone remodeling is crucial for skeletal health, and its disruption causes disorders like osteoporosis. New genomic tools are identifying targets for future bone disease therapies.
Area of Science:
- Skeletal Biology
- Genetics
- Pharmacology
Background:
- Bone turnover, involving osteoclasts and osteoblasts, is vital for skeletal integrity.
- Disruptions in bone turnover lead to age-related skeletal disorders like osteoporosis.
- Current treatments excel at inhibiting bone resorption but lack anabolic agents.
Purpose of the Study:
- To highlight the importance of bone turnover regulation.
- To discuss the limitations of current skeletal disorder therapeutics.
- To emphasize the potential of new genomic and genetic tools in drug development for bone diseases.
Main Methods:
- Review of existing literature on bone biology and endocrinology.
- Analysis of emerging genomic and genetic findings related to osteoclast and osteoblast activity.
- Discussion of therapeutic strategies for skeletal disorders.
Main Results:
- Bone resorption inhibitors are effective, but anabolic agents are scarce.
- New genomic and genetic discoveries are identifying novel regulatory loci.
- These loci control both osteoclast and osteoblast activity.
Conclusions:
- Understanding bone turnover regulation is key to treating skeletal disorders.
- Advanced genomic and genetic tools offer promising avenues for developing new bone anabolic therapies.
- Future drug development holds potential for addressing unmet needs in osteoporosis and related conditions.